NCT04617691View on ClinicalTrials.gov

A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

July 20, 2021

Study Completion Date

July 20, 2021

Conditions

Healthy

Interventions

DRUG

Guselkumab

Guselkumab will be administered as IV solution derived from FVP or PFS-U.

Trial Locations (1)

13353

CRS Clinical Research Services Berlin GmbH, Berlin

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT04617691 - A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants | Biotech Hunter | Biotech Hunter